CGA
HZNP

Compound Global Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Compound Global Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-51,564
Closed -$5.87M – 42
2022
Q4 		$5.87M Buy
+51,564
New +$4.28M 1.67% 26

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Compound Global Advisors's HZNP Position: Q1 2023 in Review

Compound Global Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 51,564 shares — an estimated $5.87M sold.

Compound Global Advisors first reported a position in HZNP in Q4 2022 and held it in 1 quarter. The position peaked at $5.87M in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

  • Compound Global Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Compound Global Advisors sold 51,564 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $5.87M.
  • Compound Global Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 1 quarter.
  • Compound Global Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.87M in Q4 2022.
  • 553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Compound Global Advisors's 13F filing for Q1 2023, filed 5 May 2023.